Building the science
of better absorption.

Chronic, low-grade, sterile inflammation — coined “inflammaging” by Claudio Franceschi — is now considered one of the primary biological drivers of age-related disease. Unlike acute inflammation, it persists without a resolved trigger, quietly accelerating tissue damage across multiple organ systems over decades.

Several plant polyphenols have been shown to modulate key inflammatory pathways including NF-κB signalling and NLRP3 inflammasome activation. The challenge has always been delivering sufficient systemic concentrations to where they are needed — the problem we are solving.

Autophagy — the cellular process by which damaged or dysfunctional components are degraded and recycled — declines significantly with age. Impaired autophagic flux is implicated in the accumulation of misfolded proteins and damaged organelles associated with neurodegeneration and accelerated cellular ageing.

Plant-derived compounds with autophagy-inducing activity have demonstrated compelling preclinical profiles. Their bioavailability from oral supplements, however, is highly variable and often the primary limiting factor in translating in-vitro activity to meaningful in-vivo outcomes.

Mitochondrial efficiency declines with age — driven by accumulated oxidative damage, impaired biogenesis, and disrupted mitophagy. The result is reduced cellular energy output, increased reactive oxygen species production, and a feedback loop that accelerates further mitochondrial deterioration.

Compounds that support mitochondrial health are predominantly lipophilic — poorly soluble, inconsistently absorbed, and highly sensitive to gastrointestinal conditions. Effective delivery is not an optional enhancement; it is a prerequisite for meaningful effect.

Senescent cells — those that have permanently exited the cell cycle but resist apoptosis — accumulate with age and secrete a pro-inflammatory cocktail known as the SASP (senescence-associated secretory phenotype), driving tissue dysfunction and systemic frailty.

Senolytic compounds represent one of the most active frontiers in longevity biology. Several plant-derived candidates in this space are of direct relevance to our research agenda — and again, bioavailability is the central limiting factor in translating their activity from bench to supplement.

The thread that connects them

Across all four of these biological domains, the most studied plant-derived candidates share a common limitation: they are lipophilic, poorly absorbed, and highly sensitive to gastrointestinal conditions. Longevity science has identified the right molecules. Delivery science needs to catch up. That is the work we are doing in Poland.